taking oxygen therapy. Patients may be left with feelings of anger at missed opportunities and concern for lost years of intervention and appropriate palliative care support.

**Conclusions** The diagnosis of IPF is a devastating one, which can be challenging to manage. Carers, patient groups and expert support at diagnosis were found to be invaluable to patients during this time.

**M269** THE EMOTIONAL TURMOIL OF IPF

| 1S Wilberley, 2Y Ochiai, 3R Pitt, 4N Mathieson. 1British Lung Foundation, London, UK; 2Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK |
| 10.1136/thoraxjnl-2014-206260.450 |

**Background** Our aim was to understand the emotions patients experience in IPF, from initial symptoms to IPF specialist management.

**Methods** Market research was conducted with an independent agency. Patients with IPF were asked to record a personal account of their experience on a hand-held camera. Face to face interviews with patients were conducted in their home. Carers were also interviewed to add an alternative perspective.

**Results** The sample included 13 male and 3 female patients with IPF. Patients with lung function impairment of all severities were included, five patients were treated with oxygen therapy and another had received a lung transplant.

Many patients had a very active lifestyle before developing IPF, leading to a high degree of frustration with the limitations imposed on their physical ability. A protracted time to diagnosis of a rare lung disease while symptoms progressed often led to distrust with their primary healthcare physician. Lack of expert knowledge about the condition often resulted in variable handling of the situation, with patients often finding themselves involved in a type of ‘role-reversal’ whereby they informed their primary healthcare physician about their own condition.

IPF specialists were perceived as their “guardian angels”. Despite being given a terminal diagnosis, patients felt reassured that they were receiving appropriate management for their condition. This stemmed from the perception that specialists treating them had appropriate knowledge and a feeling they were supported by the specialist team.

**Conclusions** As with other rare diseases, patients appear to gain most reassurance from HCP’s with a clear understanding of their condition. This highlights the benefit of expert multidisciplinary teams for IPF.

**M270** OBTAINING INFORMATION WHEN YOU HAVE A RARE DISEASE – THE POTENTIAL FOR IPF SUPPORT GROUPS

| 1S Wilberley, 2Y Ochiai, 3R Pitt, 4N Mathieson. 1British Lung Foundation, London, UK; 2Boehringer Ingelheim Ltd UK, Bracknell, Berkshire, UK |
| 10.1136/thoraxjnl-2014-206260.451 |

**Background** The aim was to explore the ways in which patients with IPF obtain information about their condition.

**Methods** Market research was conducted with an independent agency. Patients with IPF were asked to record a personal account of their experience on a hand-held camera. Face to face interviews with patients were conducted in their home. Carers were also interviewed to add an alternative perspective.

**Results** The sample included 13 male and 3 female patients with IPF. Patients with lung function impairment of all severities were included, five patients were treated with oxygen therapy and another had received a lung transplant.

Patients reported finding information from a variety of sources, including primary healthcare professionals, patient information leaflets, the internet, district nurses and support groups. Most valued sources of information were IPF physicians, nurse specialists and patient support groups.

Gaps identified by patients were the need for high quality information including, 1) accurate and complete information about IPF, 2) clarity on the difficulty of predicting life expectancy, 3) how to access services and benefits, 4) how palliative care can help, 5) why support groups are beneficial, 6) how to modify lifestyle as capabilities change, 7) how to live and travel with oxygen and 8) how to explain oxygen to others.

**Conclusions** Support groups are under-developed, with great potential to help patients and their carers. Support groups are well placed to provide advice for everyday living that the healthcare community may be unable to offer. There is also a need to improve the standard of written information currently available for patients with IPF.

**M271** A SURVEY OF TRAINEE EXPERIENCES IN INTERSTITIAL LUNG DISEASE

| 1C Sharp, 2M Gibbons. 1North Bristol NHS Trust, Bristol, UK; 2Royal Devon and Exeter NHS Foundation Trust, Exeter, UK |
| 10.1136/thoraxjnl-2014-206260.452 |

Interstitial lung disease (ILD) is a major area of respiratory medicine. It is important that trainees gain competence and confidence in this area.

**Methods** A survey of BTS trainee members was conducted in November 2013 to examine training provision in ILD, including trainee’s opportunities, experience and confidence in aspects of ILD.

**Results** There were 104 respondents out of a possible 574. 33% of respondents were not expecting any subspecialty clinics in ILD in the course of their training. 42% of trainees expect to spend 3 months or less attending specialist clinics. Trainee attendance at MDTs is far from guaranteed, with 45% expecting to attend less than half during their period in these hospitals.

The majority of trainees are trained in performing BAL for cell differential analysis (73%), and transbronchial biopsies (84%), however only 48% are confident performing transbronchial biopsies. Confidence interpreting investigation results increases with the frequency these are performed.

The self rated knowledge in a range of subject areas was also assessed and demonstrated that most areas were moderately well understood, however knowledge of the less frequently encountered IIPs was rated lower.

54% of trainees felt their ILD training was inadequate for SCE preparation. 94% would value a BTS Short Course on ILD to improve their knowledge and confidence.

**Discussion** This survey highlights areas where there are clear opportunities to enhance the training of registrars in ILDs. It is worth noting that some of the data is in conflict with previous BTS surveys in this area and there is the possibility of self-selection bias in the response population.

Whilst most trainees are trained in performing relevant procedures, their confidence interpreting the results of common investigations in ILD is low. To give evidence of training and

### Thorax 2014;69(Suppl 2):A1–A233

A221
competence in this area, deaneries may wish to consider request-
ing logbook evidence of procedures related to ILD, in addition
to evidence of ILD MDT attendance. There is undoubtedly a
need for a BTS short course on ILD for trainees.

M272 ESTIMATED COST AND PAYMENT BY RESULTS (PBR)
TARIFF REIMBURSEMENT FOR IDIOPATHIC PULMONARY
FIBROSIS SERVICES ACROSS 14 SPECIALIST PROVIDERS
IN ENGLAND

1C Hill, 2R Nasr, 3T Fisher, 4T Maher, 5M Spiteri, 6T Biring, 7M Parfrey, 8RK
Hoyle, 9M Gibbons, 10G Burge, 11E Scullion, 12E Adams, 13M Wickremasinghe. 1MAP
BioPharma Limited, Cambridge, UK; 2InterMune UK and Ireland Limited, London, UK;
3Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK; 4UHNS NHS Trust,
Stoke-on-Trent, UK; 5King’s College Hospital, London, UK; 6Papworth Hospital,
Cambridge, UK; 7Churchill Hospital, Oxford, UK; 8Royal Devon and Exeter Hospital,
Exeter, UK; 9Heartlands Hospital, Birmingham, UK; 10Glenfield Hospital, Leicester, UK;
11Aquarius Population Health Limited, Bristol, UK; 12Imperial College NHS Healthcare
Trust

Background Idiopathic Pulmonary Fibrosis (IPF) is an increas-
ingly important respiratory illness in the UK. Rising prevalence
of disease, emerging treatments, development of clinical guide-
lines for diagnosis and management and a NHS England service
specification1 increase demands on healthcare providers who are
required to enhance capacity or reconfigure services to manage
patients.

Aims Estimate the patient care pathways across service providers
in England compared with pathways recommended by NICE
guidelines2 and the NHS England Service Specification; in terms
of time and cost per patient by ‘diagnosis’, ‘management’ and
‘monitoring’, and then levels of reimbursement to providers for
current levels of care and those recommended.

Methods Structured interviews with clinicians and coders ascer-
tained current levels of service provision, excluding drug costs,
by 14 NHS specialist ILD providers. Data were analysed utilising
a bottom-up costing approach to estimate the total pathway
costs. Comparison with services and costs as recommended by
NICE guidelines and service specification allowed estimation of
NHS providers’ profit or loss.

Results The estimated mean cost per patient for the first year of
diagnosis, management and monitoring was £1,414, which is
approximately £418 (42%) more than is reimbursed by the PBR
tariff.3 By comparison, the equivalent cost of the NICE/service
specification pathway is approximately £477 (41%) more than
reimbursed by the tariff. In particular, it was noted that signifi-
cant staff time is required for MDT discussion, but that this is
not reimbursed.

Conclusions Results suggest that current NHS tariffs for ILD are
insufficient to support current service provision. This is true for
current levels of care as well as for the levels of care